Skip to Main Navigation
Skip to Page Content

Nomination Summary for Celebrex & Bextra (N20501)

Nominated Substances: Celecoxib (celebrex (tm)), Valdecoxib

Nomination Date: 10/08/2004

Nominator: Private Individual

Rationale: Vioxx, a popular drug used to treat arthritis, was removed from the market when it was discovered that it increased the risk of heart attack and stroke. Two other COX-2 inhibitors, Celebrex & Bextra, should be studied to determine if they have similar side effects.

NTP Principles: not specified

Status: In Review/Pending

More Detailed Information